Valneva shares among the strongest gainers in the SBF 120
The Lyon-based vaccine laboratory is making a clear recovery mid-morning in a virtually stable SBF 120. This rebound comes as an American bank has just revised its target on the stock, and as the share remains far from its long-term moving averages.
Goldman Sachs raises its target to €2.20 but maintains a sell rating
The share gains 2.75% to €2.54, among the strongest gainers in the SBF 120, while the index declines 0.03%. In this movement, analyst consensus provides a fact dated to today: Goldman Sachs raised its price target from €2.15 to €2.20, while maintaining its sell rating.
The target therefore remains below the current price by approximately 14%, which moderates the significance of this revision. Valneva is followed by the Lyon-based laboratory for vaccines against infectious diseases (Ixiaro, Dukoral, Ixchiq) and is developing with Pfizer a candidate against Lyme disease.
In Paris, where the bulk of trading is concentrated, its shares also trade as ADRs on the Nasdaq (1 ADR for 2 shares).
A rebound that leaves the share below its medium-term moving averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
After the October decline, the share rises back above its 20-day MA at €2.51 (a difference of 1.39%), but remains below the 50-day MA at €2.71, which is 6.09% higher than the current price.
The RSI at 48 is neutral: today's movement resembles a consolidation rather than a reversal. The price remains 13.73% below the 200-day MA and is down -35.76% over one year.
During the H1 2026 results, published on August 13, the company confirmed its 2026 outlook despite the persistent impact of the geopolitical context on travel, citing among the opportunities expected regulatory decisions on its Lyme disease vaccine.
From a technical perspective, the support at €2.33 and resistance at €2.86 bound the trading range.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
